Comparative study of images with pathology: Superparamagnetic iron oxide-enhanced magnetic resonance image (MRI) of splenic VX2 tumor in rats
Tóm tắt
To establish a rodent model of VX2 tumor of the spleen, to analyze relationship between the change of the signal intensity on superparamagnetic iron oxide enhanced magnetic resonance image (MRI) and pathologic change to evaluate the ability of superparamagnetic iron oxide enhanced MRI for detection of splenic metastases. 8 rodent models of VX2 tumor of spleen were established successfully. The images were obtained before and after administration of superparamagnetic iron oxide. T1-weighted spin-echo (SE) pulse sequence with a repetition time (TR) of 450 msec, and echo time (TE) of 12 msec (TR/TE=450/12) was used. The imaging parameters of T2-weighted SE pulse sequence were as follows: TR/TE=4000/128. On plain MR scanning T1-weighted splenic VX2 tumor showed hypointensity or isointensity which approximated to the SI of splenic parenchyma. Therefore all lesions were not displayed clearly. On superparamagnetic iron oxide enhancement T2WI sequence the SI of splenic parenchyma decreased obviously with percentage of signal intensity loss (PSIL) of 55.04%, But the SI of tumor was not evidently changed with PSIL of 0.87%. Nevertheless the SNR of normal splenic parenchyma around the lesions had obvious difference (P<0.001) comparatively. Therefore the contrast between tumor and spleen increased, and tumor displayed more clearly. Moreover the contrast-to-noise (CNR) between VX2 tumor and splenic parenchyma had an evident difference before and after admininstration of superparamagnetic iron oxide (P<0.001). On superparamagnetic iron oxide enhancement T1WI sequence the contrast of tumor-to-spleen is poor. Therefore it is not sensitive to characterize the lesions in spleen. On superparamagnetic iron oxide enhanced T2WI the contrast degree of lesions increases obviously. Consequently, superparamagnetic iron oxide-enhanced T2WI MRI scanning can improve the rate of detection and characterization for lesions of spleen.
Tài liệu tham khảo
Robertson F, Leander P, Ekberg O. Radiology of the spleen [J]. Eur Radiol 2001;11:80–95.
Piardi T, D’Adda F, Giampaoli F, et al. Solitary metachonous splenic metastases: an evaluation of surgical treatment [J]. J Exp Clin Cancer Res 1999;18:575–578.
Dachman AH, Buck JL, Krishnan J, et al. Primary non-Hodgkin’s splenic lymphoma [J]. Clin Radiol 1998;53:137–142.
Sandherr M, von Schilling C, Link T, et al. Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose [J]. Ann Oncol 2001;12:719–722.
Daskalogiannaki M, Prassopoulos P, Katrinakis G, et al. Splenic involvement in lymphomas. Evaluation on serial CT examinations [J]. Acta Radiol 2001;42:326–332.
Hamm B, Staks T, Tsupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in human with a new superparamagnetic iron oxide [J]. J Magn Reson Imaging 1994;4:659–668.
Weissleder R, Hahn PF, Stark DD, et al. MR imaging of splenic metastases: ferrite-enhanced detection in rats [J]. AJR Am J Roentgenol 1987;149:723–726.
Kuszyk BS, Boitnott JK, Choti MA, et al. Local tumor recurrence following hepatic cryoablation: radiologic — histopathologic correlation in a rabbit model [J]. Radiology 2000;217:477–486.
Paley MR, Mergo PJ, Torres GM, et al. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging [J]. AJR Am J Roentgenol 2000;175:159–163.
Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver [J]. Radiology 1988;168:297–301.
Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial [J]. Radiology 1995;195:489–496.
Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties [J]. Radiology 1997;204:749–756.
Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumor with MR imaging [J]. Radiology 1988;169:399–403.